Últimas noticias sobre Cutera (NASDAQ:CUTR) Bolsa

Cutera

Cutera Inc is a medical device company that specializes in designing, developing, manufacturing, marketing, and servicing laser and other energy-based aesthetics systems for practitioners internationally. Its products include enlighten, excel HR, excel V, Xeo and Trusculpt 3D among others. The company markets and sells its products under the trademarks such as Cutera, Acutip, Coolglide, Enlighten, Excel HR, Excel V, Genesis plus, Pico-genesis, Titan, Trusculpt, and Xeo among others. It derives the majority of its revenue from the United States segment. Its products enable medical practitioners to perform safe procedures including treatment for acne, body contouring, skin resurfacing and revitalization, hair and tattoo removal, removal of benign pigmented lesions, and vascular conditions.

Cutera Inc

<h3>Gainers</h3>
<ul>
<li>Gritstone Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTS#NASDAQ">GRTS</a>) shares rose 13.7% to $0.06 during Monday's after-market session. The market value of their outstanding shares is at $7.2 million. </li>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) stock increased by 6.11% to $0.92. The company's market cap stands at $17.8 million. </li>
<li>GRAIL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAL#NASDAQ">GRAL</a>) shares rose 5.64% to $14.65. The market value of their outstanding shares is at $454.9 million. </li>
<li>Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) stock moved upwards by 5.45% to $0.75. The company's market cap stands at $15.1 million. </li>
<li>Oragenics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#AMEX">OGEN</a>) stock moved upwards by 4.99% to $0.33. The market value of their outstanding shares is at $2.8 million. </li>
<li>Aura Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AURA#NASDAQ">AURA</a>) stock moved upwards by 4.93% to $9.79. The market value of their outstanding shares is at $485.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>INVO Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVO#NASDAQ">INVO</a>) shares decreased by 8.9% to $1.13 during Monday's after-market session. The market value of their outstanding shares is at $4.4 million. </li>
<li>Dogwood Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) stock fell 7.8% to $4.14. The company's market cap stands at $5.5 million. </li>
<li>Inhibikase Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKT#NASDAQ">IKT</a>) stock declined by 5.67% to $1.5. The market value of their outstanding shares is at $11.1 million. </li>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) shares declined by 5.07% to $0.33. The market value of their outstanding shares is at $6.8 million. </li>
<li>Sera Prognostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERA#NASDAQ">SERA</a>) shares decreased by 4.89% to $6.81. The company's market cap stands at $227.2 million. </li>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) shares decreased by 4.89% to $0.78. The company's market cap stands at $4.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AURA

BFRI

CTCX

CUTR

DWTX

GRAL

GRTS

INVO

OGEN

SERA

12 Health Care Stocks Moving In Monday's After-Market Session

Stephens &amp; Co. analyst George Sellers maintains Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) with a Overweight and lowers the price target from $10 to $5.

News

Price Target

Analyst Ratings

Stephens & Co. Maintains Overweight on Cutera, Lowers Price Target to $5

Piper Sandler analyst Matt O'Brien reiterates Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) with a Neutral and lowers the price target from $3 to $1.

Reiteration

Piper Sandler Reiterates Neutral on Cutera, Lowers Price Target to $1

WIIM

Cutera shares are trading lower after the company reported worse-than-expected Q2 revenue results and cut its FY24 revenue guidance.

Shares of Doximity, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) rose sharply in today's pre-market trading reported better-than-expected first-quarter financial results and issued <a href="https://www.benzinga.com/news/earnings/24/08/40269788/doximity-stock-soars-on-q1-earnings-the-details">strong FY24 revenue guidance.</a>
Doximity's first-quarter revenue increased 17% year-over-year to $126.68 million, beating the consensus estimate of $119.92 million, according to Benzinga Pro. The company reported adjusted earnings of 28 cents per share, beating analyst estimates of 22 cents per share.
Doximity shares jumped 28.6% to $33.00 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Iteris, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITI#NASDAQ">ITI</a>) rose 61.7% to $6.92 in today's pre-market trading after the company agreed to be acquired by Almaviva for $335 million.</li>
<li>FSD Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUGE#NASDAQ">HUGE</a>) gained 53% to $0.14 in pre-market trading after gaining 16% on Thursday.</li>
<li>Nauticus Robotics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KITT#NASDAQ">KITT</a>) gained 45.8% to $2.80 in pre-market trading. Nauticus Robotics partnered with Florida Atlantic University for cost-effective Aquanaut Mark 2 testing.</li>
<li>Avinger, Inc.. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) shares rose 28.3% to $1.54 in pre-market trading after reporting second-quarter results.</li>
<li>Iovance Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) gained 27.7% to $10.14 in pre-market trading after the company reported better-than-expected second-quarter financial results and issued Q3 product revenue guidance above estimates.</li>
<li>Clearmind Medicine Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMND#NASDAQ">CMND</a>) shares gained 27.7% to $1.52 in pre-market trading after declining around 8% on Thursday.</li>
<li>Marin Software Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRIN#NASDAQ">MRIN</a>) gained 27.1% to $2.30 in pre-market trading after the company announced AI-powered tool enhancements to its integrations with Reddit and X.</li>
<li>Babcock &amp; Wilcox Enterprises, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BW#NYSE">BW</a>) gained 22.5% to $1.36 following second-quarter results.</li>
<li>Sweetgreen, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) jumped 22.3% to $32.11 in pre-market trading after the company reported better-than-expected second-quarter revenue results.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>American Vanguard Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVD#NYSE">AVD</a>) shares dipped 30.8% to $5.66 in pre-market trading after the company reported worse-than-expected second-quarter financial results.</li>
<li>PubMatic, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PUBM#NASDAQ">PUBM</a>) shares declined 26.4% to $14.40 in pre-market trading after the company reported worse-than-expected second-quarter revenue results.</li>
<li>Cutera, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) shares declined 21.4% to $0.88 in pre-market trading after the company reported worse-than-expected second-quarter revenue results and cut its FY24 revenue guidance below estimates.</li>
<li>Nerdy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRDY#NYSE">NRDY</a>) declined 20.1% to $1.27 in pre-market trading after the company reported worse-than-expected second-quarter revenue results.</li>
<li>FiscalNote Holdings, Inc.  (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOTE#NYSE">NOTE</a>) shares fell 18.3% to $1.12 in pre-market trading after reporting second-quarter results.</li>
<li>Eventbrite, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EB#NYSE">EB</a>) fell 17.1% to $3.15 in today's pre-market trading after the company reported worse-than-expected second-quarter revenue results and issued FY24 revenue guidance below estimates.</li>
<li>AMMO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWW#NASDAQ">POWW</a>) shares fell 16.7% to $1.35 in pre-market trading after the company reported weak first-quarter sales.</li>
<li>Five9, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) fell 16.4% to $35.49 in pre-market trading after the company posted second-quarter results.</li>
<li>Trevena, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) fell 14.7% to $0.19 pre-market trading after the company reported second-quarter results.</li>
<li>Anew Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WENA#NASDAQ">WENA</a>) shares fell 10.1% to $1.15 in pre-market trading after gaining 17% on Thursday.</li>
</ul>
Now Read This: &lt;a href=&#8221;https://www.benzinga.com/news/earnings/24/04/38307448/investor-sentiment-decreases-further-s-p-500-falls-for-fourth-straight-session&#8221;&gt;&lt;em&gt; Investor Sentiment Decreases Further, S&amp;P 500 Falls For Fourth Straight Session&lt;/em&gt;&lt;/a&gt;

Pre-Market Outlook

Markets

Trading Ideas

AVGR

CMND

DOCS

FIVN

MASSIVE INTERACTIVE NV by Massive Interactive, Inc.

HUGE

IOVA

KITT

MRIN

NOTE

NRDY

POWW

PUBM

TRVN

WENA

Why Doximity Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket

Cutera Says Q2 Restructuring Resulted In $20M In Expense Savings On An Annualized Basis

Cutera shares are trading lower after the company reported worse-than-expected Q2 revenue results and cut its FY24 revenue guidance below estimates.

Guidance

Cutera Sees FY24 Revenue $140M-$145M vs $161.81M Est. (Prior Outlook $160M-$170M)

Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) reported quarterly sales of $34.400 million which missed the analyst consensus estimate of $38.695 million by 11.10 percent. This is a 43.81 percent decrease over sales of $61.218 million the same period last year.

Earnings

Earnings Misses

Cutera Q2 Sales $34.400M Miss $38.695M Estimate

Cutera Announces Partnership With L'Oréal Japan To Exclusively Promote, Market, Sell And Distribute SkinCeuticals To Clinics In Japan

Stephens &amp; Co. analyst George Sellers reiterates Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) with a Overweight and maintains $10 price target.

Stephens & Co. Reiterates Overweight on Cutera, Maintains $10 Price Target

Piper Sandler analyst Matt O'Brien maintains Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) with a Neutral and maintains $3 price target.

Piper Sandler Maintains Neutral on Cutera, Maintains $3 Price Target

Cutera Reaches Settlement Agreement With Lutronic Aesthetics Regarding All Litigation And Arbitration Matters; Lutronic To Pay $5.75M Within 30 Days

Cutera Reiterates FY24 Revenue $160M-$170M Vs $162.874M

Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(1.00) by 9 percent. This is a 13.49 percent increase over losses of $(1.26) per share from the same period last year. The company reported quarterly sales of $38.793 million which beat the analyst consensus estimate of $37.325 million by 3.93 percent. This is a 28.85 percent decrease over sales of $54.526 million the same period last year.

Earnings Beats

Cutera Q1 2024 Adj EPS $(1.09) Misses $(1.00) Estimate, Sales $38.793M Beat $37.325M Estimate

<h3>Gainers</h3>
<ul>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares moved upwards by 75.9% to $1.39 during Tuesday's after-market session. The market value of their outstanding shares is at $44.8 million. </li>
<li>Aesthetic Medical Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIH#NASDAQ">AIH</a>) shares rose 43.48% to $0.49. The market value of their outstanding shares is at $23.1 million. </li>
<li>Sight Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGHT#NASDAQ">SGHT</a>) shares rose 20.77% to $6.57. The market value of their outstanding shares is at $325.5 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) stock increased by 16.59% to $0.05. The market value of their outstanding shares is at $1.7 million. </li>
<li>GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) stock rose 6.41% to $3.15. The market value of their outstanding shares is at $203.0 million. As per the news, the Q4 earnings report came out 4 days ago. </li>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) stock rose 6.01% to $1.05. The market value of their outstanding shares is at $11.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Enveric Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) stock decreased by 14.1% to $0.98 during Tuesday's after-market session. The market value of their outstanding shares is at $7.1 million. </li>
<li>Acorda Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOR#NASDAQ">ACOR</a>) stock fell 12.0% to $2.2. The market value of their outstanding shares is at $2.7 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) shares declined by 7.43% to $1.62. The market value of their outstanding shares is at $15.2 million. As per the press release, Q4 earnings came out 3 days ago. </li>
<li>Mira Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) shares decreased by 6.55% to $1.0. The market value of their outstanding shares is at $14.7 million. As per the press release, Q4 earnings came out yesterday. </li>
<li>Cyclo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTH#NASDAQ">CYTH</a>) shares fell 6.17% to $1.37. The market value of their outstanding shares is at $39.3 million. </li>
<li>Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) shares decreased by 4.9% to $1.36. The market value of their outstanding shares is at $27.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACOR

BNOX

CYTH

ENVB

GLYC

IMNN

MIRA

ONMD

SGHT

12 Health Care Stocks Moving In Tuesday's After-Market Session

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining around 0.3% on Friday.
The Dow traded down 0.49% to 39,585.67 while the NASDAQ rose 0.26% to 16,444.91. The S&amp;P 500 also rose, gaining, 0.01% to 5,241.56.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/03/37889054/these-3-risk-off-stocks-with-over-3-dividend-yields-are-recommended-by-wall-streets-most"> These 3 Risk Off Stocks With Over 3% Dividend Yields Are Recommended By Wall Street&#39;s Most Accurate Analysts</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Communication services shares jumped by 0.8% on Friday.
In trading on Friday, real estate shares fell by 1.1%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
Shares of Lululemon Athletica Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lulu#NASDAQ">LULU</a>) fell more than 15% during Friday&rsquo;s session after releasing fourth-quarter results.
Lululemon posted better-than-expected results for its fourth quarter, but issued a weak forecast for the first quarter.
The company said it sees first-quarter revenue in the range of $2.175 billion to $2.2 billion versus estimates of $2.25 billion. The company anticipates first-quarter earnings of $2.35 to $2.40 per share versus estimates of $2.55 per share, according to data from Benzinga Pro.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Summit Midstream Partners, LP (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/smlp#NYSE">SMLP</a>) shares shot up 38% to $26.85 after the company announced the sale of its Utica position for $625 million.
Shares of Outlook Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/otlk#NASDAQ">OTLK</a>) got a boost, surging 19% to $8.40 after the company announced it received a positive European Union CHMP opinion for ONS-5010 as a treatment for Wet AMD.
Intellicheck, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/idn#NASDAQ">IDN</a>) shares were also up, gaining 70% to $2.98 after the company reported a year-over-year increase in fourth-quarter EPS results.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Cutera, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cutr#NASDAQ">CUTR</a>) shares dropped 29% to $1.6391 after the company reported worse-than-expected fourth quarter adjusted EPS results.
Shares of Sintx Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sint#NASDAQ">SINT</a>) were down 31% to $0.0941 after the company announced a proposed public offering of common stock.
Ispire Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ispr#NASDAQ">ISPR</a>) was down, falling 26% to $5.97 after the company announced the pricing of its public offering of 2.05 million shares of common stock at $6.00 per share.
Also Check This Out:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/03/37889060/top-3-materials-stocks-that-could-blast-off-in-q1"> Top 3 Materials Stocks That Could Blast Off In Q1</a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded down 0.5% to $80.63 while gold traded down 0.9% at $2,164.20.
Silver traded down 0.6% to $24.85 on Friday, while copper fell 1.2% to $4.0090.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were mixed today. The eurozone&rsquo;s STOXX 600 fell 0.03%, London&rsquo;s FTSE 100 jumped 0.61% while Spain&rsquo;s IBEX 35 Index rose 0.70% The German DAX rose 0.15% French CAC 40 fell 0.34% while Italy&rsquo;s FTSE MIB Index rose 0.05%.
The Ifo Business Climate indicator for Germany climbed to 87.8 in March from February&#39;s revised reading of 85.7. German import prices declined 5.9% year-over-year in January.
Retail sales volumes in the UK came in unchanged for February, while UK&rsquo;s GfK Consumer Confidence indicator came in flat at -21 in March.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed mixed on Friday, with Japan&rsquo;s Nikkei 225 gaining 0.18%, Hong Kong&rsquo;s Hang Seng Index falling 2.16%, China&rsquo;s Shanghai Composite Index falling 0.95% and India&rsquo;s S&amp;P BSE Sensex gaining 0.26%.
Foreign direct investment into China dipped by 19.9% year-over-year to CNY 215.1 billion during the first two months of the year. The annual inflation rate in Japan accelerated to 2.8% in February from 2.2% a month ago.
&nbsp;
<h3>Economics</h3>
&nbsp;
The total number of active U.S. oil rigs fell by 1 rig this week, Baker Hughes Inc reported.
Now Read This: <a href="https://www.benzinga.com/author/avi-kapoor-vedainformatics-com"> Around $5M Bet On This Communication Services Stock? Check Out These 4 Stocks Insiders Are Buying</a>

Penny Stocks

Eurozone

Commodities

Small Cap

Global

Intraday Update

ISPR

LULU

OTLK

SINT

SMLP

Gold Moves Lower; Lululemon Shares Plummet

Shares of Cutera, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cutr#NASDAQ">CUTR</a>) fell sharply during Friday&rsquo;s session after the company reported worse-than-expected <a href="https://www.benzinga.com/quote/CUTR/earnings">fourth quarter adjusted EPS results</a>.
Cutera posted adjusted loss of $1.36 per share, compared to market estimates for a loss of 94 cents per share. The company&rsquo;s quarterly sales came in at $49.540 million, versus expectations of $47.500 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Cutera shares dipped 26.5% to $1.6899 on Friday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Murano Global Investments PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrno#NASDAQ">MRNO</a>) shares jumped 147.5% to $23.94 after falling 46% on Thursday.</li>
<li>Nova LifeStyle, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvfy#NASDAQ">NVFY</a>) surged 120% to $4.0301 after gaining around 22% on Thursday.</li>
<li>BIOLASE, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/biol#NASDAQ">BIOL</a>) shares climbed 50.4% to $0.2256 after the company reported better-than-expected fourth-quarter earnings results.</li>
<li>IMAC Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/back#NASDAQ">BACK</a>) gained 41.1% to $1.8204.</li>
<li>Summit Midstream Partners, LP (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/smlp#NYSE">SMLP</a>) surged 36.1% to $26.45 after the company announced the sale of its Utica position for $625 million.</li>
<li>Outlook Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/otlk#NASDAQ">OTLK</a>) gained 32.1% to $9.30 after the company announced it received a positive European Union CHMP opinion for ONS-5010 as a treatment for Wet AMD.</li>
<li>GT Biopharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gtbp#NASDAQ">GTBP</a>) gained 27.6% to $4.86.</li>
<li>Aemetis, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amtx#NASDAQ">AMTX</a>) rose 21% to $6.21. Aemetis recently announced approval by the U.S. Citizenship and Immigration Services for a $200 million of EB-5 program investment for the Riverbank sustainable aviation fuel, production plant, the dairy renewable natural gas project, the carbon sequestration project and energy efficiency upgrades to the Keyes ethanol plant.</li>
<li>Foresight Autonomous Holdings Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/frsx#NASDAQ">FRSX</a>) gained 20.4% to $1.1796. Foresight Autonomous said Eye-Net and Softbank completed technology validation phase for connected mobility applications in Japan.</li>
<li>Intellicheck, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/idn#NASDAQ">IDN</a>) gained 19.4% to $2.09 after the company reported a year-over-year increase in fourth-quarter EPS results.</li>
<li>Worthington Steel, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ws#NYSE">WS</a>) climbed 18.8% to $37.92 as the company posted stronger-than-expected results for its third quarter on Thursday.</li>
<li>Canopy Growth Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cgc#NASDAQ">CGC</a>) rose 18.6% to $5.41.</li>
<li>Annexon, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/annx#NASDAQ">ANNX</a>) climbed 17.3% to $7.14.</li>
<li>Ocugen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocgn#NASDAQ">OCGN</a>) gained 12.5% to $1.5090 after gaining 8% on Thursday. Ocugen recently appointed Huma Qamar, MD, MPH as Chief Medical Officer.</li>
<li>Lithium Americas (Argentina) Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/laac#NYSE">LAAC</a>) rose 12.2% to $5.77.</li>
<li>Dianthus Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dnth#NASDAQ">DNTH</a>) surged 11% to $30.84 following upbeat results.</li>
<li>Griid Infrastructure Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grdi#NASDAQ">GRDI</a>) gained 10.9% to $1.22.</li>
<li>Astera Labs, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alab#NASDAQ">ALAB</a>) rose 9.6% to $70.30.</li>
<li>FedEx Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fdx#NYSE">FDX</a>) rose gained 7.9% to $285.78 after the company reported better-than-expected earnings for its third quarter and authorized a new $5 billion share repurchase program.</li>
<li>Foot Locker, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fl#NYSE">FL</a>) rose 5% to $24.85. Citigroup analyst Paul Lejuez upgraded Foot Locker from Sell to Neutral and announced a $24 price target.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>BYND Cannasoft Enterprises Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcan#NASDAQ">BCAN</a>) shares fell 36.4% to $2.32. BYND Cannasoft said that the previously announced 1-for-190 reverse stock split of its outstanding shares of common stock has been made effective today, March 22, 2024.</li>
<li>Sintx Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sint#NASDAQ">SINT</a>) fell 30.4% to $0.0946 after the company announced a proposed public offering of common stock.</li>
<li>Ispire Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ispr#NASDAQ">ISPR</a>) fell 28% to $5.84 after the company announced the pricing of its public offering of 2.05 million shares of common stock at $6.00 per share.</li>
<li>Brand Engagement Network, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bnai#NASDAQ">BNAI</a>) declined 27.2% to $8.00.</li>
<li>Nkarta, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nktx#NASDAQ">NKTX</a>) fell 22.2% to $10.10 after the company reported fourth-quarter financial results. Following earnings, Raymond James downgraded the stock from Strong Buy to Outperform.</li>
<li>Yield10 Bioscience, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/yten#NASDAQ">YTEN</a>) fell 22.7% to $0.3358. Yield10 Bioscience recently announced that the USDA-APHIS Biotechnology Regulatory Services determined that the Camelina sativa varieties may be planted and bred in the United States.</li>
<li>ReTo Eco-Solutions, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/reto#NASDAQ">RETO</a>) declined 20% to $1.50.</li>
<li>Aterian, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ater#NASDAQ">ATER</a>) fell 18.3% to $2.66.</li>
<li>Lixiang Education Holding Co., Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lxeh#NASDAQ">LXEH</a>) dipped 18% to $0.6026.</li>
<li>Lululemon Athletica Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lulu#NASDAQ">LULU</a>) tumbled 16.6% to $399.36. Lululemon posted better-than-expected results for its fourth quarter, but issued a weak forecast for the first quarter.</li>
<li>TROOPS, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/troo#NASDAQ">TROO</a>) declined 16.3% to $1.3798.</li>
<li>Li-Cycle Holdings Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/licy#NYSE">LICY</a>) dipped 14% to $1.1096.</li>
<li>Cazoo Group Ltd (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/czoo#NYSE">CZOO</a>) fell 13.8% to $4.0480.</li>
<li>Selina Hospitality PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/slna#NASDAQ">SLNA</a>) fell 12.9% to $0.2439 after jumping around 30% on Thursday.</li>
<li>Grifols, S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grfs#NASDAQ">GRFS</a>) fell 11.3% to $6.01.</li>
<li>Abits Group Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abts#NASDAQ">ABTS</a>) dipped 9.9% to $0.6991 after declining over 6% on Thursday.</li>
<li>Bitdeer Technologies Group (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/btdr#NASDAQ">BTDR</a>) fell 9.8% to $7.17.</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kc#NASDAQ">KC</a>) fell 9.2% to $3.2950.</li>
<li>Next.e.GO N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/egox#NASDAQ">EGOX</a>) shares fell 9% to $0.0458 after dipping 16% on Thursday.</li>
<li>NIKE, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nke#NYSE">NKE</a>) shares tumbled 8.1% to $92.63. Nike reported upbeat earnings and sales results for its third quarter on Thursday.</li>
<li>JOANN Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/joan#NASDAQ">JOAN</a>) shares fell 7.8% to $0.1420 after surging 14% on Thursday.</li>
<li>AAR Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/air#NYSE">AIR</a>) fell 5.9% to $60.14 following downbeat sales.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/24/03/37891280/bitcoin-falls-below-65-000-ondo-solana-among-top-losers"> Bitcoin Falls Below $65,000; Ondo, Solana Among Top Losers </a>

ABTS

ALAB

AMTX

ANNX

ATER

BACK

BCAN

BIOL

BNAI

BTDR

CZOO

DNTH

EGOX

FRSX

GRDI

GRFS

GTBP

JOAN

LAAC

LICY

LXEH

MRNO

NKTX

NVFY

OCGN

RETO

SLNA

TROO

YTEN

Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>IMAC Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BACK#NASDAQ">BACK</a>) shares moved upwards by 91.5% to $2.47 during Friday's regular session. The market value of their outstanding shares is at $2.8 million. </li>
<li>Virios Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRI#NASDAQ">VIRI</a>) shares increased by 37.98% to $0.46. The company's market cap stands at $8.8 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock increased by 36.71% to $5.25. The company's market cap stands at $68.3 million. </li>
<li>Ontrak (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>) shares moved upwards by 35.03% to $0.35. The market value of their outstanding shares is at $9.6 million. </li>
<li>Outlook Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTLK#NASDAQ">OTLK</a>) shares rose 27.13% to $8.95. The market value of their outstanding shares is at $193.1 million. </li>
<li>Biolase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOL#NASDAQ">BIOL</a>) shares increased by 25.4% to $0.19. The market value of their outstanding shares is at $3.6 million. As per the press release, Q4 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) shares declined by 30.4% to $0.09 during Friday's regular session. </li>
<li>Nkarta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTX#NASDAQ">NKTX</a>) stock decreased by 28.51% to $9.28. The company's market cap stands at $455.3 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) shares decreased by 25.87% to $1.71. The market value of their outstanding shares is at $34.0 million. The company's, Q4 earnings came out yesterday. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) stock decreased by 20.41% to $2.77. The market value of their outstanding shares is at $2.0 million. </li>
<li>Zura Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZURA#NASDAQ">ZURA</a>) stock fell 20.07% to $2.31. The company's market cap stands at $99.5 million. </li>
<li>Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) shares declined by 19.61% to $0.78. The market value of their outstanding shares is at $139.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATNF

OTRK

SGMO

VIRI

ZURA

12 Health Care Stocks Moving In Friday's Intraday Session

Catalyst Watch: Nike earnings, Datadog event, Norfolk Southern decision, and an oil field-crypto IPO

Wall Street Breakfast: The Week Ahead

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Celebrity beauty brand stocks can be exceptionally exciting prospects when first looking at them. After all, they have the endorsement of celebrities to build advertising off of, which tends to get people in the door early on. However, these trends fade as first consumers recognize the overpriced nature of products that perform relatively the same as non-branded ones.&nbsp;



This then leads these celebrity beauty brand stocks to dip in value, causing severe losses for investors who bought into the initial hype. Moreover, these brands tend to <a href="https://culted.com/did-you-know-that-celebrity-beauty-brands-are-killing-the-industry/">lack the longevity</a> necessary to offer long-term returns. Rather, these companies are often purchased by larger conglomerates after their value fades and treated as another portfolio asset.



This is due to the fact that most celebrity beauty products are only worth the name of their endorsement. Their chemistry and products often tend to be similar to legacy or drugstore brands, just with flashier marketing. Thus, it is imperative for investors to carefully avoid the following stocks as their value shrinks due to dipping revenues from consumer wariness.&nbsp;



<h2>COTY (COTY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/05/coty-stock-1-300x169.jpg" alt="The Coty (COTY) logo on a glass office in Poland."><div>Source: Konektus Photo / Shutterstock.com</div></div>Having lost nearly <a href="https://www.google.com/finance/quote/COTY:NYSE?sa=X&amp;ved=2ahUKEwjD5t7_hv6GAxWS_QIHHaEgBsAQ3ecFegQIPxAh">20%</a> of its value over the last six months COTY (NYSE:<a href="https://investorplace.com/stock-quotes/coty-stock-quote/">COTY</a>) is feeling the effects of consumer awareness regarding celebrity brands. The company had previously <a href="https://www.beautypackaging.com/contents/view_breaking-news/2023-08-31/is-kylie-taking-her-brand-back-from-coty/#:~:text=Coty%20bought%20a%2051%25%20stake,for%20%24600%20million%20in%202020.">acquired Kylie Jenner&rsquo;s beauty brand</a>, Kylie Cosmetics, in an attempt to bolster its portfolio with her strong follower base.



This, however, has not had much impact on the company&rsquo;s net income bleed. For example, as of its Q1 earnings report for the year, the company lost over 96% of its income, reducing profit margins down to 0.27.



This is concerning for investors in the company because it signals difficulty generating profit even a revenue bump. Should consumer trends continue to avoid COTY&rsquo;s brands, this issue could become even more severe.



<h2>elf Beauty (ELF)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/04/cosmetics-beauty-products-300x169.jpg" alt="a collection of various cosmetic products on a black table"><div>Source: Africa Studio/Shutterstock.com</div></div>While not directly endorsed or founded by any major celebrities, elf Beauty (NYSE:<a href="https://investorplace.com/stock-quotes/elf-stock-quote/">ELF</a>) could be on the verge of a correction. The company&rsquo;s products are undoubtedly of higher quality than the average competitor in the market, but its current price-to-earnings ratio of <a href="https://www.google.com/finance/quote/ELF:NYSE?sa=X&amp;ved=2ahUKEwjfn9uvh_6GAxVu3AIHHd7aAO4Q3ecFegQIQBAf">96.88x</a> is concerning in comparison to the broader industry.



This <a href="https://www.investing.com/news/company-news/piper-sandler-maintains-overweight-rating-on-elf-beauty-shares-93CH-3493671">overweight</a> appearance comes amid a 47.87% decrease in profit margins which could spell future troubles for the company despite its strong revenues. What&rsquo;s more, the company has done little to expand its brand image beyond the boutique appearance it currently commands.&nbsp;



Thus, without broadening its market and managing its income more effectively, the company could see its share value drop after the earnings report should these trends continue. If the company can broaden its market exposure and begin to compete with the cosmetics giants of the beauty industry, then it may be able to regain trust in its current share valuation of around $200.



<h2>Cutera (CUTR)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/04/skincare-1600-300x169.jpg" alt="woman smiling with white background"><div>Source: Odua Images via Shutterstock</div></div>Endorsed by the broader Hollywood industry, Cutera (NASDAQ:<a href="https://investorplace.com/stock-quotes/cutr-stock-quote/">CUTR</a>) and its novel body-shaping techniques have become something of a penny stock in comparison to its trading price a few years ago. Now several hedge funds are shorting 38.47% of its total shares. Some meme investors may expect this to result in a short squeeze they can profit from. However, the reality is that the company is simply losing too much revenue to stay valuable.



Moreover, the company itself <a href="https://finance.yahoo.com/news/why-hedge-funds-shorting-cutera-060434821.html">projected</a> $160 million to $170 million in sales for 2024 and a lower-than-expected $55 million to $60 million in cash by the end of the year. Pair this with a 29% decrease YOY for its Q1 revenue and Cutera becomes a stock to stay away from.



While its technologies may be exciting and <a href="https://www.laservelvet.com/skin-rejuvenation/carbon-laser-peel/#:~:text=Also%20known%20as%20a%20%E2%80%9CHollywood,%2C%20back%2C%20hands%20and%20chest.">endorsed by Hollywood</a>, investors should also remember that its market is relatively small. After all, the average American cannot afford the pricey machines it sells or even the treatments its practitioners offer.



On the date of publication, Viktor Zarev&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<div>Viktor Zarev is a scientist, researcher, and writer specializing in explaining the complex world of technology stocks through dedication to accuracy and understanding.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/07/investor-alert-3-ugly-celebrity-beauty-brand-stocks-not-worth-your-dollar/">Investor Alert: 3 Ugly Celebrity Beauty Brand Stocks Not Worth Your Dollar </a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Investor Alert: 3 Ugly Celebrity Beauty Brand Stocks Not Worth Your Dollar

Cutera&nbsp; GAAP EPS of -$1.23 misses by $0.02, revenue of $34.4M misses by $4.29M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Cutera (NASDAQ:<a href="https://investorplace.com/stock-quotes/cutr-stock-quote/">CUTR</a>) just reported results for the second quarter of 2024.<ul><li>Cutera reported earnings per share of -$1.06. This was below the analyst estimate for EPS of -97 cents.</li><li>The company reported revenue of $34.38 million.</li><li>This was 11.15% worse than the analyst estimate for revenue of $38.69 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/cutr-stock-earnings-cutera-for-q2-of-2024/">CUTR Stock Earnings: Cutera Misses EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CUTR Stock Earnings: Cutera Misses EPS, Misses Revenue for Q2 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
We have all of the biggest pre-market stock movers that traders need to know about on Friday morning!



Moving stocks this morning and more earnings reports, an acquisition deal, liquidation news and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Iteris (NASDAQ:<a href="https://investorplace.com/stock-quotes/iti-stock-quote/">ITI</a>) stock is rocketing more than 62% <a href="https://www.nasdaq.com/press-release/iteris-be-acquired-almaviva-335-million-2024-08-09">alongside an acquisition deal</a>.</li>



<li>Nauticus Robotics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kitt-stock-quote/">KITT</a>) shares are soaring over 61% on a <a href="https://www.nasdaq.com/press-release/nauticus-robotics-enters-aquanaut-mark-2-testing-partnership-fau-2024-08-08">new testing partnership</a>.</li>



<li>FSD Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/huge-stock-quote/">HUGE</a>) stock is surging more than 37% alongside heavy pre-market trading.</li>



<li>Bone Biologics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bblg-stock-quote/">BBLG</a>) shares are gaining over 30% with the <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318504957&amp;type=PDF&amp;symbol=BBLG&amp;cdn=81b72413280ee9face7494c21cc37055&amp;companyName=Bone+Biologics+Corp&amp;formType=ARS&amp;formDescription=Annual+Report+to+Security+Holders&amp;dateFiled=2024-08-08">release of its annual report</a>.</li>



<li>Pitney Bowes (NYSE:<a href="https://investorplace.com/stock-quotes/pbi-stock-quote/">PBI</a>) stock is rising more than 30% on plans to <a href="https://finance.yahoo.com/news/pitney-bowes-liquidate-ecommerce-unit-221312483.html">liquidate its e-commerce unit</a>.</li>



<li>Marin Software (NASDAQ:<a href="https://investorplace.com/stock-quotes/mrin-stock-quote/">MRIN</a>) shares are increasing over 28% after <a href="https://www.businesswire.com/news/home/20240808458407/en/Marin-Software-Extends-Reach-with-Reddit-and-X-Support">adding support for Reddit and X</a>, previously called Twitter.</li>



<li>Clearmind Medicine (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmnd-stock-quote/">CMND</a>) stock is heading more than 27% higher without any clear news this morning.</li>



<li>Doximity (NYSE:<a href="https://investorplace.com/stock-quotes/docs-stock-quote/">DOCS</a>) shares are climbing over 27% on a <a href="https://www.marketwatch.com/story/doximity-shares-rally-after-beating-1q-earnings-guidance-expectations-b9ce97d7?mod=markets">fiscal Q1 earnings beat</a>.</li>



<li>Satellogic (NASDAQ:<a href="https://investorplace.com/stock-quotes/satl-stock-quote/">SATL</a>) stock is jumping more than 26% today.</li>



<li>Babcock &amp; Wilcox (NYSE:<a href="https://investorplace.com/stock-quotes/bw-stock-quote/">BW</a>) shares are up over 25% after releasing its <a href="https://www.businesswire.com/news/home/20240808728017/en/Babcock-Wilcox-Enterprises-Reports-Second-Quarter-2024-Results-Earnings-Growth-Driven-By-Strong-Operating-Performance">Q2 earnings report</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>AN2 Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/antx-stock-quote/">ANTX</a>) stock is diving more than 33% <a href="https://www.nasdaq.com/press-release/an2-therapeutics-provides-update-ebo-301-phase-2-3-study-evaluating-epetraborole">with a clinical trial update</a>.</li>



<li>American Vanguard (NYSE:<a href="https://investorplace.com/stock-quotes/avd-stock-quote/">AVD</a>) shares are tumbling over 29% with the <a href="https://www.nasdaq.com/press-release/american-vanguard-reports-q2-2024-results-2024-08-08">release of its latest earnings report</a>.</li>



<li>PubMatic (NASDAQ:<a href="https://investorplace.com/stock-quotes/pubm-stock-quote/">PUBM</a>) stock is taking a more than 27% beating on <a href="https://www.stocktitan.net/news/PUBM/pub-matic-announces-second-quarter-2024-financial-zmrbbq0dmfh8.html">missed Q2 revenue</a>.</li>



<li>Eventbrite (NYSE:<a href="https://investorplace.com/stock-quotes/eb-stock-quote/">EB</a>) shares are sliding over 23% alongside <a href="https://www.tipranks.com/news/company-announcements/eventbrite-announces-layoffs-and-welcomes-new-coo-cfo">layoffs and leadership changes</a>.</li>



<li>Beauty Health (NASDAQ:<a href="https://investorplace.com/stock-quotes/skin-stock-quote/">SKIN</a>) stock is decreasing more than 22% after <a href="https://www.nasdaq.com/press-release/beautyhealth-reports-second-quarter-2024-financial-results-2024-08-08">posting its Q2 earnings report</a>.</li>



<li>Cutera (NASDAQ:<a href="https://investorplace.com/stock-quotes/cutr-stock-quote/">CUTR</a>) shares are dropping over 21% with its <a href="https://www.nasdaq.com/press-release/cuterar-announces-second-quarter-2024-financial-results-2024-08-08">latest earnings news</a>.</li>



<li>Microvast (NASDAQ:<a href="https://investorplace.com/stock-quotes/mvst-stock-quote/">MVST</a>) stock is falling more than 19% after releasing its <a href="https://ir.microvast.com/static-files/b376f438-a4e5-4a1a-ac22-a6107e450b24">Q2 2024 earnings</a>.</li>



<li>FiscalNote (NYSE:<a href="https://investorplace.com/stock-quotes/note-stock-quote/">NOTE</a>) shares are slipping over 18% after <a href="https://finance.yahoo.com/news/fiscalnote-holdings-inc-note-reports-231505554.html">posting a Q2 loss</a>.</li>



<li>Nerdy (NYSE:<a href="https://investorplace.com/stock-quotes/nrdy-stock-quote/">NRDY</a>) stock is dipping more than 18% after <a href="https://www.nasdaq.com/press-release/nerdy-announces-second-quarter-2024-financial-results-2024-08-08">releasing its Q2 earnings report</a>.</li>



<li>Five9 (NASDAQ:<a href="https://investorplace.com/stock-quotes/fivn-stock-quote/">FIVN</a>) shares close out our pre-market stock movers down over 15% with its <a href="https://www.nasdaq.com/press-release/five9-surpasses-1-billion-annual-revenue-run-rate-2024-08-08">most recent earnings report</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-aug-9th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Piper Sandler Sticks to Their Hold Rating for Cutera (CUTR)

Maxim Group analyst Anthony Vendetti has maintained their neutral stance on CUTR stock, giving a Hold rating yesterday. Anthony Vendetti has given ...

Cutera's Hold Rating Affirmed Amid Financial Challenges and Operational Headwinds

Cutera, Inc (CUTR) Q2 2024 Earnings Call Transcript

An announcement from Cutera ( ($CUTR) ) is now available. Cutera, Inc. faces a challenge as its stock price has fallen below Nasdaq's minimum requi...

Cutera Navigates Stock Woes and CTO Departure

AIRC

ANTX

AOUT

AVAV

BBLG

BNED

CLLS

COTY

CROX

DDOG

DECK

DHAI

EDRY

EXPD

ILMN

INSM

INSW

KDLY

KNOP

LCID

LEVI

LSTR

MODN

MVST

NVGS

ONON

OSTX

PANL

PAYX

PHAT

QCOM

RCKT

REAL

SATL

SBUX

SKIN

WBTN

WKME

XAIR

ZNTL

Press Releases

Cutera Announces First Quarter 2024 Financial Results

Cutera, Inc. Investor Alert (NASDAQ: CUTR): Schubert Jonckheer & Kolbe LLP Investigating Potential Claims Against the Company's Officers and Directors

Cutera, Inc. Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

Cutera® Announces AviClear® Investor Webinar

Cutera® Appoints Jeryl L. Hilleman to Board of Directors

Cutera® Announces New Survey Data During Acne Awareness Month

Cutera® to Announce Second Quarter Results on August 8, 2024

Cutera® Announces Exclusive Distribution Agreement With L'Oréal® for SkinCeuticals® Products in Japan

Comments

Cutera

Noticias

Últimas noticias sobre Cutera (NASDAQ:CUTR) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL